<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03462108</url>
  </required_header>
  <id_info>
    <org_study_id>RV 0117</org_study_id>
    <nct_id>NCT03462108</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Rotavirus (Bio Farma) Vaccine in Adults, Children &amp; Neonates</brief_title>
  <official_title>A Prospective Intervention Phase I Study in Three Age De-escalating Group to Assess the Safety and Immunogenicity of Rotavirus (Bio Farma) Vaccine in Adults, Children &amp; Neonates</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PT Bio Farma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PT Bio Farma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to assess the safety of Rotavirus (Bio Farma) vaccine in adults, children and
      neonates.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To describe the safety of this vaccine after each immunization. To assess preliminary
      information of immunogenicity following Rotavirus (Bio Farma) vaccine immunization.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 9, 2018</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Adults and Children Group: Experimental, open labeled, prospective intervention study
Neonates Group: Experimental, randomized, double blind, prospective intervention study</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>The study for the neonates is double-blind, randomized study. While, the study for the adults and childrens is open-labeled study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Solicited symptoms after each immunization</measure>
    <time_frame>0-7 days</time_frame>
    <description>Number of subjects with solicited systemic and gastrointestinal symptoms in the day 0-7 following each dose of investigational product</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events of Rotavirus (Bio Farma) vaccine</measure>
    <time_frame>28 days</time_frame>
    <description>Number and percentage of subjects with unsolicited Adverse Events (AE) in the day 0-28 following each dose of investigational product</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events of Rotavirus (Bio Farma) vaccine</measure>
    <time_frame>28 days</time_frame>
    <description>Number and percentage of subjects with Serious Adverse Events (SAE) within 28 days after each dose of investigational product</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events of Rotavirus (Bio Farma) vaccine compare to placebo in neonates group</measure>
    <time_frame>28 days</time_frame>
    <description>Number and percentage of subject with adverse event (AE) within 28 days after each dose of investigational product compare to placebo (in neonates group)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events of Rotavirus (Bio Farma) vaccine compare to placebo in neonates group</measure>
    <time_frame>28 days</time_frame>
    <description>Number and percentage of subject with Serious Adverse Events (SAE) within 28 days after each dose of investigational product compare to placebo (in neonates group)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subject who has abnormality value of routine hematology and biochemical evaluation that probably related to the vaccination</measure>
    <time_frame>7 days</time_frame>
    <description>Deviation in routine hematology and biochemical evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Excretion of rotavirus in stools in neonates group</measure>
    <time_frame>3-7 days</time_frame>
    <description>Number of neonates with rotavirus excretion in stools</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with &gt;=3 times increasing antibody from baseline to post investigational product dosing</measure>
    <time_frame>4-6 weeks after last immunization</time_frame>
    <description>Subjects with &gt;=3 times increasing antibody from baseline to post investigational product dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum anti-rotavirus immunoglobulin (Ig)A following immunization</measure>
    <time_frame>4-6 weeks after last immunization</time_frame>
    <description>Serum anti-rotavirus immunoglobulin (Ig)A before and after last immunization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum neutralizing antibody (SNA) following immunization</measure>
    <time_frame>4-6 weeks after last immunization</time_frame>
    <description>Serum neutralizing antibody (SNA) before and after last immunization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer (GMT) following immunization</measure>
    <time_frame>4-6 weeks after last immunization</time_frame>
    <description>Geometric mean titer (GMT) before and after last immunization</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Safety Issues</condition>
  <arm_group>
    <arm_group_label>Rotavirus (Bio Farma) Vaccine-Adult</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 doses of 1 ml of Rotavirus vaccine per oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rotavirus (Bio Farma) Vaccine-Children</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 doses of 1 ml of Rotavirus vaccine per oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rotavirus (Bio Farma) Vaccine-Neonates</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 doses of 1 ml of Rotavirus vaccine per oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-Neonates</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3 doses of 1 ml of Placebo (contains 30% sucrose in DMEM) per oral</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rotavirus (Bio Farma) Vaccine</intervention_name>
    <description>3 doses of Rotavirus (Bio Farma) Vaccine</description>
    <arm_group_label>Rotavirus (Bio Farma) Vaccine-Adult</arm_group_label>
    <arm_group_label>Rotavirus (Bio Farma) Vaccine-Children</arm_group_label>
    <arm_group_label>Rotavirus (Bio Farma) Vaccine-Neonates</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>3 doses of Placebo contains 30% sucrose in DMEM</description>
    <arm_group_label>Placebo-Neonates</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Adults:

          -  Healthy Adults as determined by clinical judgment, including a medical history,
             physical exam and laboratory results, which confirms the absence of a current or past
             disease state considered significant by the investigator.

          -  Subjects have been informed properly regarding the study and signed the informed
             consent form.

          -  Subject will commit to comply with the instructions of the investigator and the
             schedule of the trial.

        Inclusion Criteria for Children:

          -  Healthy Children as determined by clinical judgment, including a medical history and
             physical exam, which confirms the absence of a current or past disease state
             considered significant by the investigator.

          -  Parents/guardian(s) have been informed properly regarding the study and signed the
             informed consent form

          -  Parent/guardian(s) will commit to comply with the instructions of the investigator and
             the schedule of the trial.

        Inclusion Criteria for Neonates:

          -  Neonate 0-5 days of age at the time of first dose, with cord blood available

          -  Neonate is in good health as determined by clinical judgment, including a medical
             history and physical exam, which confirms the absence of a current or past disease
             state considered significant by the investigator.

          -  The neonate was born full term (minimum of 36 completed weeks and maximum of 42
             completed weeks gestation).

          -  Neonate birth weight 2500-4000 g inclusive.

          -  Parents or guardians have been informed properly regarding the study and signed the
             informed consent form

          -  Parents or guardians will commit to comply with the instructions of the investigator
             and the schedule of the trial

        Exclusion Criteria for Adults:

          -  Subject concomitantly enrolled or scheduled to be enrolled in another trial

          -  Any direct relatives relationship with the study team.

          -  Evolving mild, moderate or severe illness, especially infectious diseases or fever
             (axillary temperature ³ 37.5°C) within the 48 hours preceding enrollment.

          -  Known history of allergy to any component of the vaccines

          -  Known history of immunodeficiency disorder (HIV infection, leukemia, lymphoma, or
             malignancy)

          -  Gastroenteritis in the 24 hours preceding enrollment.

          -  History of uncontrolled coagulopathy or blood disorders contraindicating for
             phlebotomy.

          -  Subject who has received in the previous 4 weeks a treatment likely to alter the
             immune response (intravenous immunoglobulins, blood-derived products, or
             corticosteroid therapy and other immunosuppresant).

          -  Subject consuming or expect to consume a probiotics within one week before and after
             vaccination

          -  Any abnormality or chronic disease which according to the investigator might interfere
             with the assessment of the trial objectives.

          -  Pregnancy &amp; lactation (Adults).

          -  Subject already immunized with any vaccine within 4 weeks prior and expects to receive
             other vaccines within 4 weeks following immunization.

          -  Subject planning to move from the study area before the end of study period.

        Exclusion Criteria for Children:

          -  Subject concomitantly enrolled or scheduled to be enrolled in another trial

          -  Any direct relatives relationship with the study team

          -  Evolving mild, moderate or severe illness, especially infectious diseases or fever
             (axillary temperature ³ 37.5°C ) within the 48 hours preceding enrollment

          -  Known history of allergy to any component of the vaccines

          -  Known history of immunodeficiency disorder (HIV infection, leukemia, lymphoma, or
             malignancy)

          -  Gastroenteritis in the 24 hours preceding enrollment.

          -  Any clinically significant history of chronic gastrointestinal disease including
             uncorrected congenital malformation of gastrointestinal tract that would predispose
             for Intusussception.

          -  History of uncontrolled coagulopathy or blood disorders contraindicating for
             phlebotomy.

          -  Subject who has received in the previous 4 weeks a treatment likely to alter the
             immune response (intravenous immunoglobulins, blood-derived products or corticosteroid
             therapy and other immunosuppresant).

          -  Subjects consuming or expect to consume a probiotics within one week before and after
             vaccination.

          -  Any abnormality or chronic disease which according to the investigator might interfere
             with the assessment of the trial objectives.

          -  Individuals who have previously received any rotavirus vaccine.

          -  Subject already immunized with any vaccine within 4 weeks prior and expects to receive
             other vaccines within 4 weeks following immunization.

          -  Subject planning to move from the study area before the end of study period

        Exclusion Criteria for Neonates:

          -  Subject concomitantly enrolled or scheduled to be enrolled in another trial.

          -  Any direct relatives relationship with the study team.

          -  Evolving mild, moderate or severe illness, especially infectious diseases or fever
             (axillary temperature ³ 37.5°C) within the 48 hours preceding enrollment.

          -  Subject with known or suspected history of allergy to any component of the vaccines.

          -  Subject with a biological mother with a known or suspected human immunodeficiency
             virus (HIV) infection.

          -  Subject with known or suspected major congenital malformations or genetically
             determined disease.

          -  Subject with intussusception.

          -  Subject with a known or suspected disease of uncontrolled coagulopathy or blood
             disorders contraindicating for phlebotomy.

          -  Subject with a known or suspected disease of the immune system or those who has
             received immunosuppresive therapy, including immunosuppresive courses of systemic
             corticosteroid.

          -  Subject who have ever received any blood products, including immunoglobulin, or for
             whom receipt of any blood product during the course of study.

          -  Any abnormality or chronic disease which according to the investigator might interfere
             with the assessment of the trial objectives.

          -  Subject immunized with non- EPI vaccines.

          -  Gastroenteritis in the 24 hours preceding enrollment.

          -  Subject planning to move from the study area before the end of study period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jarir At Thobari</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pediatric Research Office (PRO), Departemen Ilmu Kesehatan Anak, Fakultas Kedokteran UGM/RSUP Dr. Sardjito</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novilia Sjafri Bachtiar</last_name>
    <phone>62222033755</phone>
    <phone_ext>14101</phone_ext>
    <email>novilia@biofarma.co.id</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gantiwarno Primary Health Center</name>
      <address>
        <city>Klaten</city>
        <state>Central Java</state>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klaten Selatan Primary Health Center</name>
      <address>
        <city>Klaten</city>
        <state>Central Java</state>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ngawen Primary Health Center</name>
      <address>
        <city>Klaten</city>
        <state>Central Java</state>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>RS Soeradji Tritonegoro</name>
      <address>
        <city>Klaten</city>
        <state>Central Java</state>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2017</study_first_submitted>
  <study_first_submitted_qc>March 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2018</study_first_posted>
  <last_update_submitted>April 12, 2018</last_update_submitted>
  <last_update_submitted_qc>April 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

